Notice of Proposed Sale · 144
Royalty Pharma plc
RPRXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Royalty Pharma plc
- Issuer CIK
- 0001802768
- SEC file number
- 001-39329
- Phone
- (212) 883-0200
- Person for whose account securities are to be sold
- Urist Marshall
- Relationships to issuer
- Officer
- Street
- 110 EAST 59TH STREET
- City
- NEW YORK
- State / country code
- NY
- Postal code
- 10022
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 4,126 | 238,812.88 | 445,277,344 | 09/28/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 225 Liberty Street
- Street (continued)
- Floor 37
- City
- New York
- State / country code
- NY
- Postal code
- 10281
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Class A Ordinary Shares | 08/05/2026 | Equity Performance Award | Royalty Pharma plc | 4,126 | N | 08/05/2026 | Granted as part of issuer equity compensation program |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Marshall Urist | Common Stock | 05/14/2026 | 13,684 | 726,137.82 |
| Marshall Urist | Common Stock | 05/20/2026 | 13,684 | 721,837.21 |
| Marshall Urist | Common Stock | 06/24/2026 | 9,098 | 502,066.55 |
| Marshall Urist | Common Stock | 07/01/2026 | 9,099 | 508,453.82 |
Seller — prior-sale row 1, entry 1
- Name
- Marshall Urist
- Street
- 110 EAST 59TH STREET
- City
- New York
- State / country code
- NY
- Postal code
- 10022
Seller — prior-sale row 2, entry 1
- Name
- Marshall Urist
- Street
- 110 EAST 59TH STREET
- City
- New York
- State / country code
- NY
- Postal code
- 10022
Seller — prior-sale row 3, entry 1
- Name
- Marshall Urist
- Street
- 110 EAST 59TH STREET
- City
- New York
- State / country code
- NY
- Postal code
- 10022
Seller — prior-sale row 4, entry 1
- Name
- Marshall Urist
- Street
- 110 EAST 59TH STREET
- City
- New York
- State / country code
- NY
- Postal code
- 10022
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 09/28/2026
- Signed
- Marshall Urist
- Plan adoption dates
- 06/26/2026
Company context
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.